Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRZ1 | P23471 | 4/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | CETP | P11597 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | UBE2M | P61081 | 1/20 | 0.38 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3278395 | 0.81 | CETP (0.42) | PTPRZ1PTPN1CETPFFAR4UBE2M | |
| SCHEMBL12300586 | 0.81 | CETP (0.41) | PTPRZ1PTPN1CETPFFAR4UBE2M | |
| SCHEMBL5729617 | 0.81 | PNMT (0.44) | PTPRZ1PTPN1CETPFFAR4TSHR | |
| SCHEMBL4039392 | 0.81 | CETP (0.42) | PTPRZ1PTPN1CETPFFAR4UBE2M | |
| SCHEMBL2692232 | 0.81 | CETP (0.42) | PTPRZ1PTPN1CETPFFAR4UBE2M | |
| SCHEMBL7052463 | 0.81 | PTPRZ1 (0.41) | PTPRZ1PTPN1CETPFFAR4UBE2M | |
| SCHEMBL5422754 | 0.81 | PTPRZ1 (0.41) | PTPRZ1PTPN1CETPFFAR4UBE2M | |
| Hydrochloric Acid SCHEMBL25368843 | 0.79 | PNMT (0.42) | PTPRZ1PTPN1CETPFFAR4KDM4E | |
| Hydrochloric Acid SCHEMBL30580130 | 0.79 | PNMT (0.42) | PTPRZ1PTPN1CETPFFAR4KDM4E | |
| SCHEMBL13064250 | 0.78 | CETP (0.40) | PTPRZ1PTPN1CETPFFAR4UBE2M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329727-B2 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329727-B2 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2454243-A2 | TETRAZOLE DERIVATIVES | Merck Serono SA (CH) | 2012-05-23 | — | — | EP | disclosed |
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2012-05-10 | — | — | US | disclosed |
| WO-2011006935-A2 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-01-20 | — | — | WO | disclosed |
| US-7790730-B2 | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation | GILEAD SCIENCES, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790730-B2 | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation | GILEAD SCIENCES, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100028301-A1 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-02-04 | — | — | US | disclosed |
| US-20100028301-A1 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-02-04 | — | — | US | disclosed |
| US-7648998-B2 | 5-((3-(4-chlorophenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine; hepatitis-C-virus | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2010-01-19 | — | — | US | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
| US-20060270649-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2006-11-30 | — | — | US | disclosed |
| US-6858603-B2 | Acetindine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040235816-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2004-11-25 | — | — | US | disclosed |
| CN-1149191-C | Azetidine derivatives, Preparation and medicines containing them | ���ĵ�˹ҩ��ɷ�����˾ | 2004-05-12 | — | — | CN | disclosed |
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2003-08-28 | — | — | US | disclosed |
| US-6518264-B2 | For treatment/prevention of psychoses, other brain disorders, and cardiovascular disorders | AVENTIS PHARMA S.A. (FR) | 2003-02-11 | — | — | US | disclosed |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2002-03-21 | — | — | US | disclosed |
| CN-1316991-A | Azetidine derivatives, preparation and medicines containing them | AVENTIS PHARMA SA (FR) | 2001-10-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235816-A1 | Azetidine derivatives, their preparation and medicaments containing them | AZI2, ADRA2A, ADRA2C | PTPRZ1 604/4885PTPN1 2114/4885CETP 2236/4885 |
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | TSLP, IL5, CMA1 | PTPRZ1 574/4885PTPN1 2776/4885CETP 531/4885 |
| US-20100028301-A1 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | CYP3A5, TPMT, ZC3HAV1 | PTPRZ1 441/4885PTPN1 559/4885CETP 3157/4885 |
| US-20060270649-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | AZI2, QDPR, ADRA2A | PTPRZ1 491/4885PTPN1 2174/4885CETP 2251/4885 |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | ZC3HAV1, TPMT, DPP4 | PTPRZ1 366/4885PTPN1 594/4885CETP 2592/4885 |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | CYP11B2, AZI2, CYP2C19 | PTPRZ1 1590/4885PTPN1 1842/4885CETP 1993/4885 |
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | ADRA1D, ADRB2, AZI2 | PTPRZ1 2607/4885PTPN1 4156/4885CETP 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.